Mitomycin medac 40 mg pulveris un šķīdinātājs intravezikāli lietojama šķīduma pagatavošanai Latvija - latviešu - Zāļu valsts aģentūra

mitomycin medac 40 mg pulveris un šķīdinātājs intravezikāli lietojama šķīduma pagatavošanai

medac gesellschaft für klinische spezialpräparate mbh, germany - mitomicīns - pulveris un šķīdinātājs intravezikāli lietojama šķīduma pagatavošanai - 40 mg

Allopurinol Orifarm 100 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

allopurinol orifarm 100 mg tabletes

orifarm healthcare a/s, denmark - allopurinols - tablete - 100 mg

Entonox 50%/50% medicīniskā gāze, saspiesta Latvija - latviešu - Zāļu valsts aģentūra

entonox 50%/50% medicīniskā gāze, saspiesta

linde sverige ab, sweden - dinitrogenii oxidum, skābekļa - medicīniskā gāze, saspiesta - 50%/50%

Allopurinol Orifarm 300 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

allopurinol orifarm 300 mg tabletes

orifarm healthcare a/s, denmark - allopurinols - tablete - 300 mg

Duzallo Eiropas Savienība - latviešu - EMA (European Medicines Agency)

duzallo

grunenthal gmbh - alopurinols, lesinurad - podagra - antigut preparāti - duzallo ir norādīts ārstēšanai pieaugušajiem hyperuricaemia, podagru pacientiem, kam nav sasniegts mērķa seruma urīnskābes līmeni ar pietiekamu devu alopurinols vien.

Allopurinol Accord 100 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

allopurinol accord 100 mg tabletes

accord healthcare b.v., netherlands - allopurinols - tablete - 100 mg

Allopurinol Accord 300 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

allopurinol accord 300 mg tabletes

accord healthcare b.v., netherlands - allopurinols - tablete - 300 mg

Serynox 50%/50% medicīniskā gāze, saspiesta Latvija - latviešu - Zāļu valsts aģentūra

serynox 50%/50% medicīniskā gāze, saspiesta

elme messer l, sia, latvia - dinitrogenii oxidum, skābekļa - medicīniskā gāze, saspiesta - 50%/50%

Zolsketil pegylated liposomal Eiropas Savienība - latviešu - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doksorubicīns - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.